CTRI/2018/06/014573
Completed
未知
A comparative evaluation of safety and efficacy of formoterol with tiotropium bromide and formoterol with glycopyrronium in patients of COPD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Health Condition 1: null- chronic obstructive pulmonary diseaseHealth Condition 2: J449- Chronic obstructive pulmonary disease, unspecifiedHealth Condition 3: J449- Chronic obstructive pulmonary disease, unspecified
- Sponsor
- Department of pharmacology
- Enrollment
- 160
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •patients with grade II and III COPD in age group of 18 \- 65 of both genders will be enrolled in the study
Exclusion Criteria
- •Complicated cases of COPD patients
- •Patients with clinically significant lung disease other than COPD
- •Patients with respiratory failure
- •Patients who are on systemic corticosteroid therapy
- •Pregnant and Lactating patients.
- •Psychotic patients.
- •Critically ill patients.
- •Patients with comorbid conditions like myocardial infarction, diabetes mellitus 5
- •Known cases of HIV/HBsAg /Anti\-HCV and immuno\-compromised patients.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
To study and compare the effect of prednisolone acetate and nepafenac eyedrops in patients after surgery for cloudy lens (safed motiya)Health Condition 1: H269- Unspecified cataractCTRI/2023/01/049131Pt B D Sharma PGIMS Rohtak43
Not yet recruiting
Phase 2
Comparison of the effect of Tulsi and Chlorhexidine mouth rinse on gum disease in controlled sugar patients aged 45-55 years in Davangere city.CTRI/2019/01/016960il
Not yet recruiting
Phase 2
A clinical trial to study the effects of two drugs, metformin lotion and zinc oxide cream in patients with melasma, a type of facial pigmentatioHealth Condition 1: L811- ChloasmaCTRI/2023/09/057901ITHYAMS
Not yet recruiting
Phase 4
To assess and compare the effectiveness and safety of olopatadine 0.7 percent and alcatadine 0.25 percent in patients with allergic conjunctivitis.CTRI/2024/05/067217Pt B.D. Sharma UHS Rohtak
Unknown
Not Applicable
Comparison between 3 surgical treatments in stable vitiligo patientsHealth Condition 1: L80- VitiligoCTRI/2019/11/021900GCS Medical college Hospital and Research center6